ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical
Trending on TikTok(35,000+)

Tirzepatide

Tirzepatide

Also known as: Mounjaro, Zepbound, LY3298176

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Tirzepatide

Dual agonism of GIP and GLP-1 receptors for synergistic metabolic effects. Enhances glucose-dependent insulin secretion via both incretin pathways.

Dosing Information

Half-Life

~5 days

Typical Dose

2.5–15 mg

Frequency

Once weekly

Cycle Length

Ongoing / indefinite under medical supervision

Administration Routes:
subcutaneous

Benefits

  • Industry-leading weight loss (up to 22% body weight in trials)
  • Superior glycemic control vs GLP-1 agonists alone
  • Improved insulin sensitivity
  • Reduction in liver fat and inflammation
  • Favorable cardiovascular risk profile
  • Improved triglycerides and lipid markers

Side Effects

Nausea and gastrointestinal discomfortmild
Diarrhea or constipationmild
Decreased appetite (can be excessive)mild
Injection site reactionsmild
Potential pancreatitis risk (rare)mild

Mechanism of Action

1

Dual agonism of GIP and GLP-1 receptors for synergistic metabolic effects

2

Enhances glucose-dependent insulin secretion via both incretin pathways

3

Slows gastric emptying and reduces appetite centrally

4

Improves beta-cell function and insulin sensitivity in adipose tissue

Contraindications

Do not use this peptide if any of the following apply:

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of severe pancreatitis
  • Severe renal impairment

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)
Duration2-4 weeks

Research Summary

Preclinical

The SURMOUNT-1 trial showed tirzepatide 15 mg produced an average weight loss of 22.5% over 72 weeks in participants with obesity, with over one-third of participants achieving ≥25% weight loss. SURPASS trials demonstrated HbA1c reductions of up to 2.6% in type 2 diabetes. FDA-approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).

Frequently Asked Questions

Common questions about Tirzepatide

UK-Specific Information

Exclusive data points and guidance for UK residents using Tirzepatide

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok